Skip to content
Screener

Price / book at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
29.8×+19.8×
Arrowhead Research logo
Arrowhead ResearchARWR
14.3×+11.7×
Assembly Biosciences logo
Assembly BiosciencesASMB
2.2×-0.4×
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
3.4×-5.1×
Wave Life Sciences logo
Wave Life SciencesWVE
2.5×-5.2×
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
2.4×+1.5×

Other financials

Income statement

See full
Revenue$1.3B+66.9%
Gross profit$992.7M+57.2%
Operating income$231.4M+1,529%
Net income$164.5M+348%
EPS (diluted)$1.21+337%

Balance sheet

See full
Cash & equivalents$1.7B+53.2%
Total debt$256.4M-5.2%
Total equity$1.4B+440%
Total assets$5.6B+21.7%

Cash flow

See full
Operating cash flow$326.7M+113%
CapEx$34.7M+143%
Free cash flow$292.0M+109%

Valuation

See full
Market cap$27.5B-50.0%
Enterprise value$26.05B-51.9%
P/E37.5×
P/S5.7×-16.6×

Profitability

See full
Gross margin79.8%-4.1pp
Operating margin20.8%+16.5pp
Net margin15.3%+10.7pp
FCF margin16.5%+14.8pp

Returns & leverage

See full
Return on equity91.4%
Debt / equity0.2×-0.9×
Current ratio3.1×+0.3×

Where this comes from

Calculated from Alnylam Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →

Filed
Jul 30, 2026, 8:11 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001178670-26-000062

FAQ

What is Alnylam Pharmaceuticals's price / book?
Alnylam Pharmaceuticals (ALNY) reported price / book of 29.7× in Q2 2026.
How has Alnylam Pharmaceuticals's price / book changed year-over-year?
Alnylam Pharmaceuticals's price / book decreased by 82.4% year-over-year, from 169.1× to 29.7×.
What is the long-term trend for Alnylam Pharmaceuticals's price / book?
Over 3 years (2020 to 2025), Alnylam Pharmaceuticals's price / book has grown at a 63.3% compound annual growth rate (CAGR), from 15.3× to 66.6×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Alnylam Pharmaceuticals's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude